CINECA IRIS Institutional Research Information System

MASSAIA, Massimo Giovanni Stefano
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 10.526
EU - Europa 7.907
AS - Asia 4.885
SA - Sud America 412
AF - Africa 187
OC - Oceania 53
Continente sconosciuto - Info sul continente non disponibili 29
Totale 23.999
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.320
CN - Cina 2.323
SG - Singapore 1.447
DE - Germania 1.267
IT - Italia 1.208
SE - Svezia 1.004
IE - Irlanda 877
UA - Ucraina 774
FR - Francia 656
FI - Finlandia 559
AT - Austria 457
KR - Corea 368
BR - Brasile 346
GB - Regno Unito 331
PL - Polonia 231
IN - India 175
CA - Canada 162
VN - Vietnam 161
SN - Senegal 112
NL - Olanda 101
HK - Hong Kong 92
GR - Grecia 71
RU - Federazione Russa 68
JP - Giappone 66
DK - Danimarca 58
ID - Indonesia 56
BE - Belgio 51
AU - Australia 49
MX - Messico 35
TR - Turchia 35
ES - Italia 32
CH - Svizzera 26
EU - Europa 26
UZ - Uzbekistan 26
BY - Bielorussia 25
AR - Argentina 21
TW - Taiwan 21
PT - Portogallo 20
ZA - Sudafrica 20
CL - Cile 17
HU - Ungheria 16
IR - Iran 13
NO - Norvegia 13
TH - Thailandia 13
EG - Egitto 12
MA - Marocco 12
MU - Mauritius 12
RO - Romania 12
SA - Arabia Saudita 12
CO - Colombia 11
CZ - Repubblica Ceca 10
PK - Pakistan 10
IL - Israele 9
IQ - Iraq 9
RS - Serbia 9
BD - Bangladesh 8
MK - Macedonia 8
PE - Perù 8
DZ - Algeria 7
LT - Lituania 6
LU - Lussemburgo 6
EC - Ecuador 5
KZ - Kazakistan 5
PH - Filippine 5
AE - Emirati Arabi Uniti 4
AM - Armenia 4
NP - Nepal 4
NZ - Nuova Zelanda 4
SY - Repubblica araba siriana 4
HN - Honduras 3
HR - Croazia 3
JO - Giordania 3
TN - Tunisia 3
AP - ???statistics.table.value.countryCode.AP??? 2
AZ - Azerbaigian 2
CU - Cuba 2
LK - Sri Lanka 2
LV - Lettonia 2
NG - Nigeria 2
OM - Oman 2
PY - Paraguay 2
SI - Slovenia 2
TG - Togo 2
A1 - Anonimo 1
AL - Albania 1
AO - Angola 1
BG - Bulgaria 1
BW - Botswana 1
CI - Costa d'Avorio 1
CR - Costa Rica 1
CY - Cipro 1
DO - Repubblica Dominicana 1
GA - Gabon 1
GI - Gibilterra 1
JM - Giamaica 1
KG - Kirghizistan 1
KH - Cambogia 1
MD - Moldavia 1
MO - Macao, regione amministrativa speciale della Cina 1
PA - Panama 1
Totale 23.994
Salva come PNG Salva come JPEG
Città #
Beijing 1.709
Chandler 1.226
Dublin 874
Singapore 825
Santa Clara 775
Jacksonville 521
Ashburn 503
Houston 449
Vienna 442
Ann Arbor 410
Villeurbanne 355
Medford 322
Nyköping 318
Fairfield 298
Dearborn 290
Princeton 281
Wilmington 264
Columbus 244
Torino 226
Warsaw 215
Woodbridge 191
San Mateo 182
Munich 166
Turin 146
Seattle 139
Milan 135
Redwood City 125
Fremont 117
Cambridge 106
Pisa 96
Helsinki 95
Dong Ket 93
Boston 82
Boardman 80
Toronto 80
New York 67
Washington 66
Shanghai 64
Guangzhou 58
Hong Kong 57
Düsseldorf 54
Jakarta 53
Rome 47
Nanjing 45
Pune 43
Hefei 42
Norwalk 40
Brussels 37
Los Angeles 37
Falls Church 36
Verona 36
Nürnberg 35
São Paulo 35
Mountain View 33
Hangzhou 29
Phoenix 29
Tokyo 28
Nuremberg 27
Lachine 26
Paris 26
Kunming 25
Chengdu 24
San Diego 24
Falkenstein 21
Florence 21
Lappeenranta 20
Raritan 20
Ottawa 19
Frankfurt am Main 18
Philadelphia 18
Jinan 17
London 17
Hebei 15
Taipei 15
Wuhan 15
Chennai 14
Dallas 14
Duncan 14
Nanchang 14
Rio de Janeiro 14
Amsterdam 13
Bologna 13
Silver Spring 13
Changsha 12
Des Moines 12
Mumbai 12
Rotterdam 12
San Jose 12
Athens 11
Shenyang 11
Central District 10
Fuzhou 10
Hyderabad 10
Istanbul 10
Marseille 10
Mexico City 10
Padova 10
Piemonte 10
Seoul 10
Bogotá 9
Totale 14.009
Salva come PNG Salva come JPEG
Nome #
Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients 482
Stem cell transplantation in multiple myeloma and other plasma cell disorders (report from an EBMT preceptorship meeting) 436
A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia 370
Clinicopathologic spectrum of cutaneous diseases in patients with hematologic malignancies with or without allogeneic bone marrow transplantation: an observational cohort study in 101 patients. 344
REGULATION OF HIF-1 alpha IN TP53 DISRUPTED CHRONIC LYMPHOCYTIC LEUKEMIA CELLS AND ITS POTENTIAL ROLE AS A THERAPEUTIC TARGET 299
IGHV unmutated CLL B cells are more prone to spontaneous apoptosis and subject to environmental prosurvival signals than mutated CLL B cells 298
Management of multiple myeloma and related-disorders: guidelines from the Italian Society of Hematology (SIE), Italian Society of Experimental Hematology (SIES) and Italian Group for Bone Marrow Transplantation (GITMO) 294
The ATP-binding cassette transporter A1 regulates phosphoantigen release and Vγ9Vδ2 T cell activation by dendritic cells 264
Chicago 2014 - 30 years of γδ T cells 245
Anergic bone marrow Vγ9Vδ2 T cells as early and long-lasting markers of PD-1-targetable microenvironment-induced immune suppression in human myeloma 213
The Defective Proliferation of Vgamma9Vdelta2 T Cells to Zoledronic Acid In Chronic Lymphocytic Leukemia (CLL) Is a Powerful Time to First Treatment (TFT) Predictor Associated with the IGHV Mutational Status. 206
Regulation of HIF-1α in TP53 disrupted chronic lymphocytic leukemia cells and its potential role as a therapeutic target 205
Increasing intratumor C/EBP-β LIP and nitric oxide levels overcome resistance to doxorubicin in triple negative breast cancer 191
Practical management of ibrutinib in the real life: Focus on atrial fibrillation and bleeding 187
Fludarabine plus alemtuzumab (FA) front-line treatment in young patients with chronic lymphocytic leukemia (CLL) and an adverse biologic profile 183
Unmutated IGHV1-69/D3-16/J3 Stereotyped HCDR3 Rearrangements (Subset 6) Are Associated with Indolent Disease Course and Have Outcome Independent of Mutational Status In Early Stage CLL (Rai 0) 180
Zoledronic Acid Restores Doxorubicin Chemosensitivity and Immunogenic Cell Death in Multidrug-Resistant Human Cancer Cells 174
Simvastatin and downstream inhibitors circumvent constitutive and stromal cell-induced resistance to doxorubicin in IGHV unmutated CLL cells 169
HIF-1α is overexpressed in leukemic cells from TP53-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia 164
Humoral immune responses toward tumor-derived antigens in previously untreated patients with chronic lymphocytic leukemia 153
Long-term follow-up of a comparison of nonmyeloablative allografting with autografting for newly diagnosed myeloma. 149
null 148
Final Report of Bendamustine and Alemtuzumab (BEN CAM) Combination in Relapsed and Refractory Chronic Lymphocytic Leukemia 144
ABCA1, apoA-I, and BTN3A1: A Legitimate ménage à trois in dendritic cells 143
TELOMERES SHORTEN DURING CHRONIC LYMPHOCYTIC LEUKEMIA(CLL) EVOLUTION: AN ANALYSIS ON 88 CASES 141
A phase II multi-center trial of pentostatin plus cyclophosphamide with ofatumumab in older previously untreated chronic lymphocytic leukemia patients 140
The Mevalonate Pathway and Downstream Signal Transducers As Therapeutic Targets to Overcome Multidrug Resistance in Chronic Lymphocytic Leukemia (CLL) 138
Identification of Novel Tumor-Associated Antigens in Chronic Lymphocytic Leukemia (CLL) by Serological Proteome Analysis (SERPA) 138
Immunoglobulin variable heavy-chain (Ig Vh) mutational status and tumor microenvironment interactions in B-cell chronic lymphocytic leukaemia 137
Amplification of T cell activation induced by CD73 (ecto-5' nucleotidase) engagement. 136
Vγ9Vδ2 T cells as strategic weapons to improve the potency of immune checkpoint blockade and immune interventions in human myeloma 136
Zoledronic acid repolarizes tumor-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway 134
Effective anti-tumor immunomodulatory properties of zoledronic acid 132
CD157 reduces acutemyeloid leukemia cell sensitivity tocytarabine through upregulation of MCL-1 anti-apoptotic protein 128
Vγ9Vδ2 T Cells in the Bone Marrow of Myeloma Patients: A Paradigm of Microenvironment-Induced Immune Suppression 126
IDENTIFICATION BY SEROLOGICAL PROTEOME ANALYSIS (SERPA) OF TUMOR-ASSOCIATED ANTIGENS ELICITING ANTIBODY RESPONSES IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) 126
Anticancer innovative therapy: Highlights from the ninth annual meeting 125
CD157 REGULATES THE SENSITIVITY OF ACUTE MYELOID LEUKEMIA CELLS TO CHEMOTHERAPY BY MODULATING THE APOPTOTIC RESPONSE 121
Phenotypic and Functional Features of V{gamma}9/V{delta}2 T Cells in Chronic Lymphocytic Leukemia Are Strongly Correlated with the Mutational Status of the Immunoglobulin Heavy Chain Variable Region (IgVH) and Metabolic Activity of the Mevalonate Pathway in Tumor Cells 120
A PROSPECTIVE PHASE II STUDY ON TANDEM AUTOGRAFTING-ONMYELOABLATIVE ALLOGRAFTING FOR NEWLY DIAGNOSED MULTIPLE MYELOMA: FINAL RESULTS OF A MULTICENTER GITMO (GRUPPO ITALIANO TRAPIANTO MIDOLLO OSSEO) PROTOCOL 120
Chlorambucil plus rituximab as front-line therapy for elderly and/or unfit chronic lymphocytic leukemia patients: Correlation with biologically-based risk stratification 119
The immune suppressive tumor microenvironment in multiple myeloma: The contribution of myeloid-derived suppressor cells 117
Advances in biology of multiple myeloma: cell kinetics, molecular biology and immunology. 117
The Mevalonate Pathway As a Metabolic Target to Circumvent Multidrug-Resistance in Chronic Lymphocytic Leukemia Cells 117
Progressive Telomere Shortening Is Part of the Natural History of Chronic Lymphocytic Leukemia (CLL) and Impacts Clinical Outcom 117
Low Dose TBI Based Nonmyeloablative Conditionings for Allografting in Multiple Myeloma: Impact of Disease Status at Transplant. 117
Telomere length is an independent predictor of survival, treatment requirement and Richter’s syndrome transformation in chronic lymphocytic leukemia 117
Regulation of HIF-1α in TP53 Disrupted Chronic Lymphocytic Leukemia Cells and Its Potential Role as a Therapeutic Target 117
Identification and functional characterization of tumor specific antibody responses in chronic lymphocytic leukemia 116
Multiple myeloma: altered CD4/CD8 ratio in bone marrow. 115
THE LOCAL MICROENVIRONMENT PLAYS A DIFFERENT ROLE IN THE SURVIVAL OF TUMOR CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA WITH MUTATED AND UNMUTATED IMMUNOGLOBULIN (IG) VH GENES 115
The tryptophan metabolism in the immune dysregulation of multiple myeloma 115
Is there a role for allografting in myeloma ?: an update of a comparative study 112
Role of PD-1/PD-L1 axis in the immune paresis of bone marrow Vγ9Vδ2 T cells in multiple myeloma 112
IDENTIFICATION AND FUNCTIONAL CHARACTERIZATION OF ANTIBODY IMMUNE RESPONSES ELICITED BY SELF ANTIGENS IN CHRONIC LYMPHOCYTIC LEUKEMIA 112
Accelerated activity of the mevalonate pathway supports the immune escape and multidrug-resistance phenotype of IGHV unmutated chronic lymphocytic leukemia cells 111
Zoledronic acid restores doxorubicin chemosensitivity and immunogenic cell death in multidrug-resistant human cancer cells 111
Idiotype vaccination in human myeloma: generation of tumor-specific immune responses after high-dose chemotherapy. 111
Immunoglobulin M (IgM) multiple myeloma versus Waldenström macroglobulinemia: Diagnostic challenges and therapeutic options: Two case reports 111
Refractory cytopenia with multilinear dysplasia (RCMD) in patient with Fanconi anaemia 110
Long-term follow-up of idiotype vaccination in human myeloma as a maintenance therapy after high-dose chemotherapy 109
Targeting the mevalonate pathway and downstream signaling pathways as a strategy to circumvent multidrug-resistance in CLL cells 109
A Score-Based Approach to18F-FDG PET Images as a Tool to Describe Metabolic Predictors of Myocardial Doxorubicin Susceptibility 108
PROGRESSIVE TELOMERE SHORTENING DURING THE NATURAL HISTORY OF CHRONIC LYMPHOCYTIC LEUKEMIA 108
IMPACT OF THE MEVALONATE PATHWAY AND HIF/PGP AXIS IN MODULATING MULTIDRUG-RESISTANCE IN UNMUTATED CLL CELLS 107
Expression of telomeric proteins in chronic lymphocytic leukemia (CLL) 107
Serological Proteome Analysis (SERPA) as a tool for the identification of novel tumor antigens in chronic lymphocytic leukemia (CLL) 106
Progressive telomere shortening occurs during the natural history of chronic lymphocytic leukemia (CLL) and associates to outcome 106
[Idiotypic study of human myeloma] 103
Telomere lenght measurement in the clinically oriented research setting: a comparison between Southern blot (SB), real time quantitative PCR (RQ-PCR) and FLOW-FISH (FF) 103
The metabolism of mevalonate as a signaling pathway influencing tumor-host interactions and disease progression in chronic lymphocytic leukemia (CLL) 103
B cells from chronic lymphocytic leukemia (CLL) patients are strong inducers of proliferation and major histocompatibility complex (MHC)-unrestricted [natural killer (NK)-like] cytotoxicity in normal T-lymphocytes. 103
Difference in polyamine transport in human B and T lymphocytes. 102
Telomere Length Is An Independent Predictor of Survival, Treatment Requirement and Richter’s Syndrome Transformation in Chronic Lymphocytic Leukemia 101
Dysfunctional Vγ9Vδ2 T cells are negative prognosticators and markers of dysregulated mevalonate pathway activity in chronic lymphocytic leukemia cells. 101
Identification by serological proteome analysis (SERPA) of tumor-associated antigens eliciting antibody-responses in chronic lymphocytic leukemia 101
Differential Effects of Microenvironmental Elements On Tumor Cells Survival in Chronic Lymphocytic Leukemia Patient Subsets with Good or Poor Prognosis 100
Dendritic Cells Can Be Primed to Concurrently Activate Both Unconventional Gamma/delta and Conventional alpha/beta T Cells 99
[Prognostic factors in multiple myeloma] 98
SEROLOGICAL PROTEOME ANALYSIS (SERPA) FOR THE IDENTIFICATION OF TUMOR-ASSOCIATED ANTIGENS ELICITING ANTIBODY-RESPONSES IN CHRONIC LYMPHOCYTIC LEUKEMIA 98
CD157 signaling promotes survival of acute myeloid leukemia cells and modulates sensitivity to cytarabine through regulation of anti-apoptotic Mcl-1. 98
Comprehensive assessment of the TCRBV repertoire in small T-cell samples by means of an improved and convenient multiplex PCR method 97
IGHV Unmutated Chronic Lymphocytic Leukemia (CLL) B Cells Are More Susceptible to Spontaneous Apoptosis Than Mutated CLL B Cells and Are Subject to the Anti-Apoptotic Effect of Environmental Signals 97
Identification by serological proteome analysis (SERPA) of novel tumor associated antigens in chronic lymphocytic leukemia (CLL) 97
The bone marrow of myeloma patients is steadily inhabited by a normal-sized pool of functional regulatory T cells irrespective of the disease status. 97
Lack of correlation between plasma cell thymidine labelling index and serum beta-2-microglobulin in monoclonal gammopathies. 96
Immune Modulation by Zoledronic Acid in Human Myeloma: An Advantageous Cross Talk between V{gamma}9V{delta}2 T Cells, {alpha}{beta} CD8+ T Cells, Regulatory T Cells, and Dendritic Cells 96
Activated idiotype-reactive cells in suppressor/cytotoxic subpopulations of monoclonal gammopathies:correlation with diagnosis and disease status. 96
Cytobiological studies in multiple myeloma. 95
Biochemical evidence for the presence of abnormal B lymphocytes in the peripheral blood of multiple myeloma patients. 95
Serological proteome analysis (SERPA) as a tool for the identification of tumor antigens capable of eliciting immune responses in chronic lymphocytic leukemia (CLL) 95
A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study 95
Molecular prediction of durable remission after first-line fludarabinecyclophosphamide-rituximab in chronic lymphocytic leukemia 94
Early CPAP prevents evolution of acute lung injury in patients with hematologic malignancy. 94
BENDAMUSTINE AND ALEMTUZUMAB (BEN CAM) COMBINATION IN RELAPSED AND REFRACTORY CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL): PHASE I SAFETY PROFILE RESULTS OF THE ITALIAN TRIAL 94
Progressive telomere shortening is part of the natural history of chronic lymphocytic leukaemia and impacts clinical outcome: Evidences from long term follow-up 93
HIF-1 alpha Upregulation in TP53 Disrupted Chronic Lymphocytic Leukemia Cells and Its Potential Role As a Therapeutic Target 93
Regulatory T Cells (Tregs) Are Highly Preserved in Multiple Myeloma Patients and Can Dominate Effector Functions 92
Microvesicles released from multiple myeloma cells are equipped with ectoenzymes belonging to canonical and non-canonical adenosinergic pathways and produce adenosine from ATP and NAD. 92
Changes in SRBC binding capacity and T-surface antigen expression on human peripheral blood lymphocytes stimulated by 12-0-tetradecanoilphorbol-13-acetate (TPA). 91
Totale 13.997
Salva come PNG Salva come JPEG
Categoria #
all - tutte 79.858
article - articoli 0
book - libri 0
conference - conferenze 29.396
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 109.254
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020612 0 0 0 0 0 0 0 0 0 252 207 153
2020/20212.693 271 155 170 156 291 125 175 134 321 209 377 309
2021/20223.011 108 89 91 218 123 57 463 159 104 326 648 625
2022/20233.960 415 321 93 347 353 997 312 255 415 132 204 116
2023/20241.918 225 363 120 101 110 344 53 104 15 104 132 247
2024/20253.942 37 294 199 501 1.269 252 217 296 550 327 0 0
Totale 24.848